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In November and December 2008, six cases of suspect wound 
botulism were reported in heroin injecting drug users, all residents 
in Dublin, Ireland. Patients were aged between 23-42 years of age; 
four cases were male; one patient died shortly after admission. 
The patients presented to four different hospitals across the city. 
Botulism in injecting drug users in Ireland was last reported in 
2002. 
On Monday, 24 November 2008, public health authorities were 
notified that an injecting drug user (IDU) had been admitted to a 
hospital in Dublin, Ireland, with neurological signs suggestive of 
botulism including progessive bulbar palsy, diplopia, dysarthria, 
and an electromyography (EMG) test consistent with a diagnosis 
of botulism. The patient was treated with botulism anti-toxin and 
supportive measures. Serum samples taken prior to administration 
of anti-toxin were sent to the Foodborne Pathogen Reference 
Unit, London, United Kingdom (UK) for detection of Clostridium 
botulinum neurotoxin by mouse biotoxin assay. Laboratory results 
confirmed the diagnosis of botulism and identified the causative 
toxin as C. botulinum toxin type B. 
By Friday, 28 November, three additional suspected cases of 
botulism had been notified, all of whom received anti-toxin. These 
four patients were admitted to three different hospitals in Dublin. 
Although two patients lived in the same area, they did not know 
each other. All were IDUs, but there was no evidence that they 
shared the same drug supply. 
No additional cases were notified to the Departments of Public 
Health in Ireland during the week beginning on 1 December. 
However, during the 36-hour period from 8 to 10 December, two 
further patients were admitted to a fourth Dublin hospital with 
signs suggestive of botulism (difficulty breathing and speaking, 
ataxia, double vision). Both patients received botulism anti-toxin. 
Unfortunately, one of these patients died shortly after admission 
from overwhelming sepsis. At the time of writing this report, one 
case is laboratory confirmed, two cases are probable and three cases 
are possible (see next section and Table for further details). 
For the purpose of this investigation, a possible case of drug 
injection-related wound botulism was defined as a person in the 
Republic of Ireland with a recent history (within four weeks of 
symptom onset) of injecting drug use and with acute onset since 1 
November 2008 of either of the following symptoms in the absence 
of any other obvious cause:
• symmetrical cranial nerve palsy,
• difficulty in swallowing or speech,
• unexplained stridor,
• difficulty in breathing,
• or descending flaccid paralysis.
A probable case was defined as having the features of a possible 
case and laboratory results suggestive of C. botulinum infection but 
unconfirmed by neutralisation. 
A confirmed case was defined as having the features of a 
probable case, with a confirmed diagnosis of botulism (by detection 
of botulinum toxin in serum or isolation of C. botulinum from a 
wound or abscess site).
An outbreak enhanced surveillance form was designed (available 
upon request) to collect relevant demographic, clinical and drug use 
data. This form was filled out in as much detail possible by hospital 
staff. Specific attempts were made to identify links between the 
six patients in terms of area of residence, social networks and 
drug supply. 
A summary of selected demographic and clinical data as well 
as information about drug use of the cases is presented in the 
Table. 
The outbreak has been managed by an outbreak control team led 
by the Department of Public Health, Health Service Executive-East 
(HSE-E) in Dublin. In addition to HSE-East staff, personnel from 
the Health Protection Surveillance Centre (HPSC), Dublin, the HSE 
Drug Services, Dublin, and a clinical microbiologist from one of 
the involved hospitals were included in the outbreak control team. 
As is the norm in outbreaks of suspected clostridial infections, 
the HPSC alerted clinical staff throughout the country (emergency 
medicine physicians, neurologists, infectious disease physicians, 
microbiology services, drug services and public health medicine 
physicians) through email alerts. Press releases were also issued to 
2  EUROSURVEILLANCE  Vol .  14 ·  Issue 1 ·  8  January 2009 ·  www.eurosurveillance.org
the national media. Internationally, the European Centre for Disease 
Control (ECDC) and the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) were informed. HSE HPSC alerted 
other European countries using the Early Warning and Response 
System (EWRS), an internet based rapid alert system supported by 
the European Commission and run by ECDC. Advice in relation to 
‘skin popping’ (subcutaneous injection of heroin) with potentially 
contaminated heroin was distributed to the drug using community 
through the drug services and the network of 13 local drugs task 
forces in Dublin.
Heroin used by one patient was obtained and has been sent to 
the Foodborne Pathogen Reference Unit for testing by the Irish 
police. However, C. botulinum could not be isolated from this 
sample No other cases of wound botulism were reported in Ireland 
in 2008 apart from those reported here. There have been two cases 
of suspected wound botulism in drug users in different areas in 
the north of England since 25 December 2008. One of these is 
unconfirmed (serum sample collected several days after on set of 
symptoms), whilst testing for the second case is on going. Both 
cases had classic symptoms and have received anti-toxin. The 
authors are unaware of any other outbreak occurring European 
countries in this time period.
Discussion
Since 2000, there have been three outbreaks of clostridial 
infections in IVDUs in Dublin. In an outbreak of Clostridium novyi 
Type A in 2000, 22 patients were infected, of whom eight died 
[1-3]. A simultaneous outbreak occurred in the north of England 
and Glasgow, Scotland. In 2002, an outbreak of botulism involving 
three IDUs occurred in Ireland [4,5]. 
There is laboratory confirmation of a clinical diagnosis of botulism 
in approximately 40% of wound botulism cases, either by detection 
of botulinum neurotoxin in the patients’ serum or by isolation of 
C. botulinum from wounds. Reasons for this low confirmation rate 
include delay in recognition of clinical signs and subsequent delays 
in specimen collection. Once toxin reaches the nerve endings, it 
binds irreversibly, thus reducing the amount of toxin in the serum 
to below detectable levels. In addition, inadequate volumes of 
serum sent for testing may reduce the sensitivity of the test, and the 
administration of systemic antibiotics prior to specimen collection 
may reduce the viability of organisms in pus taken from associated 
wound abscesses.
The fact that only one case in this outbreak has been laboratory-
confirmed, with the remaining cases classified as possible or 
probable, can be attributed to the difficulties mentioned in the 
paragraph above.  Two of the cases were given anti-toxin before 
serum samples were obtained and thus toxin was not detectable. 
Wound botulism became a notifiable disease in Ireland on 
1 January 2004. Prior to this date, only food-borne botulism 
was notifiable under the disease category of Acute Infectious 
Gastroenteritis. 
Wound botulism occurring among IDUs was first reported in the 
United States in 1982 [6]. Since then both sporadic botulism cases 
and outbreaks have been reported among this sub-population. A 
number of other European countries have also reported outbreaks 
among IDUs in recent years [7-11]. 
Heroin users who inject either subcutaneously or intramuscularly 
are at particular risk, as administration using this method is 
conducive to wound infection, abscess formation and generation 
of the anaerobic conditions for germination of C. botulinum spores 
and subsequent release of neurotoxin [7]. Spores of C. botulinum 
are often present in soil and may contaminate heroin or heroin 
taking equipment.  Heating the heroin powder to solubilise it for 
subcutaneous injection does not kill the spores, and the acidulant 
used for solubilisation enhances tissue damage at the injection 
sites, facilitating the germination of botulinum spores and leading 
to release of neurotoxin. 
Botulism (both food-borne and wound) is extremely rare in Ireland, 
unlike many European countries which routinely see food-borne 
cases each year. Wound botulism is much rarer, but both sporadic 
cases and outbreaks have been reported in European countries in 
recent years [7-11]. Maintaining high levels of awareness of the risk 
of botulism among the population of injecting drug users is vital 
to insure that they are aware of the risk and urgently seek medical 
attention if they develop any of the signs or symptoms associated 
with the disease. Alerting clinicians to botulism increases the 
likelihood of rapid diagnosis, early hospitalisation and appropriate 
treatment with anti-toxin and other supportive treatment of these 
patients, thus decreasing mortality and complications. Delays in 
T a b l e 
Demographic, clinical and drug use history, reported botulism cases, Dublin, 2008
Case 
(No.) Sex
Age
(years)
Onset of 
symptoms
Clinical features/skin 
abscesses
Mechanical 
ventilation
Anti toxin 
given/date
Recent* 
heroin 
injection
Case 
classification Outcome
1 M 33 20/11/2008 Dysarthria, indurated area No
Yes
21/11/2008 Yes Confirmed Alive
2 M 23 21/11/2008 Respiratory problems Yes Yes27/11/2008 Yes Probable Alive
3 F 34 17/11/2008 Respiratory problems Yes Yes27/11/2008 Yes Possible Alive
4 M 39 21/11/2008 Respiratory problems/abscess Yes 
Yes
27/11/2008 Yes Probable Alive
5 M 38 04/12/2008 Dysarthria No Yes8/12/2008 Yes Possible Alive
6 F 42 10/12/2008 Dysarthria and ataxia/ abscess No
Yes
10/12/2008 Yes Possible Died
*within four weeks of clinical disease onset
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administration of anti-toxin treatment increase mortality, hospital 
stay and rehabilitation time. Raising the index of suspicion also 
increases the likelihood of additional cases being considered. 
Our working hypothesis is that a contaminated supply of heroin is 
responsible for this outbreak, supported by the number of cases and 
focus in the Dublin area over a short period of time. However our 
investigation to date has failed to identify common links between 
cases. Such links were identified in the clostridial outbreak among 
IDUs in Dublin in 2000 [1-3], when common social networks and 
common drug dealers were identified for some of the cases. At that 
time, similar C. novyi outbreaks were occurring in northern England 
and Glasgow, Scotland, supporting the hypothesis of a common 
contaminated supply. 
The fact that no further cases have been identified suggests 
that rapid dissemination of information and local action may have 
averted further cases. The authors would welcome hearing of any 
wound botulism cases seen in other countries around this time.
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